Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An open study in Belgium assessed the clinical efficacy and safety of auranofin (AF) in treating psoriatic arthritis. The study enrolled 29 patients; median age was 46 years and median duration of disease was 5.5 years. Patients received 6 mg AF daily, given as two 3-mg tablets once a day. Concomitant therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids was permitted. Efficacy of auranofin was apparent by 3 months after the start of treatment, as evidenced by improvement over baseline in number of tender joints, severity of pain, and erythrocyte sedimentation rate. After 1 year of auranofin therapy there was 50% or greater improvement over baseline in these parameters in 11% to 41% of the total population, and in 19% to 69% of those who completed at least 1 year of treatment. Diarrhea was reported in 45% of patients, occurring most often during the first 6 months of therapy. Nausea occurred in 10%; abdominal pain in 7%; rash in 14%; and pruritus in 17%. Withdrawals because of adverse events totaled 4: 1 for rash, 2 for pruritus, and 1 for rash, pruritus, and purpura. Auranofin may be considered an effective and safe therapeutic alternative for the treatment of psoriatic arthritis.
 ...
PMID:An open study on the efficacy and safety of auranofin in treating psoriatic arthritis. 347 79

Oral gold(Auranofin; SKF) 6 mg/d has been used in an open study in 31 patients with active rheumatoid disease, 19 of whom have been on continuous treatment for 1 year. Four of these patients were considered to be in remission and 9 had a good clinical response to treatment. Four showed only minimal improvement and 2 did not improve at all. There were, however, no changes in the biochemical parameters of inflammation, e.g. haemoglobin concentration, erythrocyte sedimentation rate, platelet count and rheumatoid factor, or in renal and hepatic function. Of the 31 patients, 9 (29%) have discontinued treatment but only 3 (9.7%) because of side-effects. Minor side-effects have been fairly common, occurring in 19 patients (61%), and included skin rashes and pruritus, diarrhoea and loose stools, nausea, stomatitis and thrombocytopenia or leucopenia. Oral gold would seem to be a safer, less potent form of chrysotherapy than parenteral gold.
 ...
PMID:An oral gold formulation in rheumatoid arthritis. A 12-month follow-up report. 681 Apr 77